Cancers & treatments·Regimen libraryAdjuvant

Intravesical BCG, induction and maintenance

Checked 2026-09-09

High-risk non-muscle-invasive bladder cancer after complete TURBT

One cycle

weekly × 6 · about 6 weeks in total

7-day cycle × 6 weekly inductions, then 3 weekly instillations at 3, 6, 12, 18, 24, 30 and 36 months (about 6 weeks)Intravesical

Components

Drug	Dose	Route	Days	Note
BCG Live bacterial immunotherapy (intravesical)	one full-dose vial (reduced dose during shortages)	Intravesical	D1	held in the bladder for 2 hours

Cycles

6 weekly inductions, then 3 weekly instillations at 3, 6, 12, 18, 24, 30 and 36 months

7-day cycle

Emetogenicity

Minimal (<10%)

G-CSF

Not routine

Used in

Bladder & urothelial cancer

Trials

POTOMAC SunRISe-1

Products

Intravesical BCG

Source

SWOG 8507 maintenance schedule; NCCN Bladder Cancer

Reference doses for a typical adult from the cited protocol or label. Doses are adjusted for renal and hepatic function, age, performance status and prior toxicity, and institutional protocols vary. Verify against the current label and your local protocol before treating. Not medical advice.

Other regimens for these cancers

Gemcitabine + cisplatin

Advanced biliary tract cancer first line (with durvalumab or pembrolizumab); cisplatin-eligible urothelial cancer

every 21 days × 8

Sacituzumab govitecan

Metastatic TNBC after two lines (one for metastatic disease); HR-positive after endocrine therapy and two chemotherapies

every 21 days

Dose-dense MVAC

Muscle-invasive bladder cancer, cisplatin-eligible, before cystectomy

every 14 days × 3-4

Enfortumab vedotin + pembrolizumab

Locally advanced or metastatic urothelial cancer, first line, regardless of cisplatin eligibility

every 21 days

All regimens Docetaxel + prednisone →